We’re excited to share that Biocytogen will be exhibiting at AusBiotech 2026 on October 19–23, 2026, on the Gold Coast, Australia! Engage with leading scientists, researchers, and industry professionals while exploring the latest advancements and innovations across the life sciences and biotechnology industry. This premier Australian life sciences event provides valuable opportunities to connect with potential partners and discuss the future of drug discovery and therapeutic development.
Visit us at Booth 56 to learn more about Biocytogen’s innovative solutions for drug discovery and preclinical research, including our AI-driven antibody discovery platform, fully human antibody discovery platforms powered by RenMice®, and genetically engineered animal models and preclinical services. Biocytogen looks forward to connecting with industry professionals and exploring new opportunities for collaboration. We hope to see you there!
AusBiotech is Australia’s premier life sciences conference, bringing together biotechnology and life sciences companies, researchers, investors, government representatives, and other industry professionals from Australia and around the world. The event provides a platform for knowledge exchange, collaboration, investment, and business development across the life sciences sector.
AusBiotech offers opportunities to explore emerging technologies, gain insights from industry leaders, and connect with potential partners across the biotechnology and healthcare ecosystem. The event brings together the diverse sectors of Australia’s life sciences industry while fostering international connections and collaboration.
Event Overview
Date: October 19–23, 2026
Venue: Gold Coast Convention & Exhibition Centre (GCCEC)
Booth: 56
Spotlight Presentation: Wednesday, October 21, 2026 | 11:15 am–11:25 am (10 mins)，Exhibition Hall – BIS Stage
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg).
We can’t wait to see you on the Gold Coast, Australia!
